Author of

• 30292

  +

  EP1.01 - Advanced NSCLC (ID 150)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Advanced NSCLC
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 30324

    +

    EP1.01-28 - Real World Use of Afatinib in NSCLC EGFRm+ Patients Outside Clinical Trials: A FAETT Experience (Now Available) (ID 655)

    08:00 - 18:00  |  Author(s): Inmaculada Fernández
    • Abstract
    • Slides

    Background
    

    Epidermal growth factor receptor (EGFR) tyrosine kynase inhibitors (TKIs) remain the standard of care as first-line therapy for patients with non-small cell lung cancer (NSCLC) harboring an EGFR mutation. These drugs have been associated with improvements in both clinical outcomes and tolerability, compared with platinum-based chemotherapy.

    Three generations of TKIs are currently approved in the first-line setting, though only first (erlotinib and gefitinib) and second generation blockers (mainly afatinib, but also dacomitinib) have been extensively used in clinical practice nowadays.

    Method
    

    We reviewed 105 patients with NSCLC with advanced or recurrent stages that harbour EGFR mutations, treated with afatinib as first´line therapy among the academic hospitals adhered to the FAETT network.
    The information of clinical, pathological and treatment characteristics of the patients was collected retrospectively and the statistical analysis was performed with the software SPSS software version 21.0, considering the statistical significance if p-value <0.05.

    Result
    

    The characteristics of the patients are reflected in Table 1.
    The mean age at the beginning of treatment with afatinib was 61 (37-81) years. 48.6% of the patients were older than 65 years. 27.6% were older than 70 years. With a median follow-up of 15 months (0-82), the median progression-free survival was 14 months (10.74-17.26) Fig 1, and the median overall survival was 31 months (24.00) -37.99).
    The median PFS and OS among patients older than 65 years, and even those older than 70 years, is not statistically significant (14 vs 13 and 30 vs 31 months, repectively. P-value:0,83 and 0,78
    On the other hand, the toxicities between both groups remain similar, with diarrhea and skin rash standing out as the most frequent, as reflected in the data published to date. Table 2

    

    

    Conclusion
    

    This retrospective study shows no differences in the use of afatinib among older patients in terms of both efficacy and tolerability.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.